STAAR Surgical Revises Strategy Amid Slow U.S. Adoption, Analyst Adjusts Rating to Market Perform
Portfolio Pulse from Vandana Singh
STAAR Surgical's slow U.S. adoption has led William Blair to downgrade the company from Outperform to Market Perform. The analyst believes that 10%+ penetration is achievable in the U.S., but it will take more time and investment than anticipated. STAAR's shares are down 5.12% at $51.99.
June 07, 2023 | 6:53 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
STAAR Surgical has been downgraded by William Blair due to slow U.S. adoption, with shares down 5.12% at $51.99. The analyst still believes 10%+ penetration is achievable but will take more time.
The downgrade by William Blair is a direct result of STAAR Surgical's slow U.S. adoption, which has impacted the company's stock price. The analyst still believes in the company's potential for growth, but the slower-than-expected progress will likely have a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100